{{medical}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460025245
| IUPAC_name = (6''R'',7''R'')-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2''Z'')-2-(2-furyl)-2-(methoxyimino) acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Cefuroxime-based-on-1QMF-2D-skeletal.png

<!--Clinical data-->
| tradename = Ceftin, Zinacef
| Drugs.com = {{drugs.com|monograph|cefuroxime-axetil}}
| MedlinePlus = a601206
| pregnancy_category = Not known to be harmful (BNF)
| legal_status = 處方藥物
| routes_of_administration = 口服、[[肌肉注射|肌肉注射]]或[[靜脈注射|靜脈注射]]

<!--Pharmacokinetic data-->
| bioavailability = 37% on empty stomach, up to 52% if taken after food
| metabolism = [[axetil|axetil]] moiety is metabolized to [[acetaldehyde|acetaldehyde]] and [[acetic_acid|acetic acid]]
| elimination_half-life = 80分鐘
| excretion = Urine 66-100% Unchanged

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 55268-75-2
| ATC_prefix = J01
| ATC_suffix = DC02
| ATC_supplemental = {{ATCvet|J51|DC02}}
| PubChem = 5361202
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = APRD00285
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4514699
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O1R9FJ93ED
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00262
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 466

<!--Chemical data-->
| C=16 | H=16 | N=4 | O=8 | S=1 
| molecular_weight = 424.386 g/mol
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3occc3)COC(=O)N)C(=O)O
| InChI = 1/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9+/t10-,14-/m1/s1
| InChIKey = JFPVXVDWJQMJEE-SWWZKJRFBX
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9+/t10-,14-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JFPVXVDWJQMJEE-SWWZKJRFSA-N
}}
[[File:20120127-CefuroximeTablets-from-TKOH-SDC13826.JPG|thumb]]
'''頭孢呋辛'''（{{lang|en|'''Cefuroxime'''}}）是一種第二代的[[頭孢類|頭孢類]][[抗生素|抗生素]]，自1977年已廣泛在美國使用，並以商品名稱'''Ceftin'''發售；而這種藥在香港亦有在醫院裡處方。現時這種藥的專利由[[葛蘭素史克|葛蘭素史克]]藥廠擁有，並以'''新菌靈'''™（'''Zinnat'''®）<ref name=zinnat>{{cite web |url=http://www.gsk.com.hk/ProductPopUp.aspx?ID=76&ProductType=prescription |title=Zinnat® |publisher=[[葛蘭素史克|葛蘭素史克]]藥廠}}</ref>的名稱發售，並分為靜脈注射劑及125 mg、250 mg、500 mg三個份量的丸劑<ref name=zinnat />。

== 主治 ==
如同其他的頭孢菌素，雖然頭孢呋辛是一種第二代頭孢菌素，它對[[β內醯胺酶|β內醯胺酶]]的抵抗力比較弱，所以對抗[[嗜血流感桿菌|嗜血流感桿菌]]、[[淋球菌|淋球菌]]及[[萊姆病|萊姆病]]的活躍程度較高。而與其他第二代頭孢菌素不同的是：頭孢呋辛可以通過[[血腦屏障|血腦屏障]]。

== 副作用 ==
頭孢呋辛的耐受性普遍良好，即使有副作用也只是暫時性。常見的副作用包括有：腹瀉、噁心、嘔吐、頭痛或偏頭痛、頭暈或腹痛，但醫護人員在給藥後一般都會向病人詢問其藥後反應。它在餐後服用會吸收得較好，產生的副作用也比較少。

過往有文獻指頭孢呋辛跟[[盤尼西林|盤尼西林]]類藥物有10%的[[交叉過敏|交叉過敏]]風險，但現時已證實不管是頭孢呋辛還是其他第二代及往後的頭孢類抗生素均不會增加盤尼西林的交叉過敏風險<ref name="pmid16451776">{{cite journal |author=Pichichero ME |title=Cephalosporins can be prescribed safely for penicillin-allergic patients |journal=The Journal of family practice |volume=55 |issue=2 |pages=106–12 |year=2006 |pmid=16451776 |doi= |url=http://www.jfponline.com/pdf%2F5502%2F5502JFP_AppliedEvidence1.pdf |format=PDF |deadurl=yes |archiveurl=https://web.archive.org/web/20120224193547/http://www.jfponline.com/pdf%2F5502%2F5502JFP_AppliedEvidence1.pdf |archivedate=2012-02-24 }}</ref>。

== 參考資料 ==
{{reflist}}

== 外部連結 ==
{{commonscat|Cefuroxime}}

{{CephalosporinAntiBiotics}}
{{GlaxoSmithKline}}

[[Category:Cephalosporin_antibiotics|Category:Cephalosporin antibiotics]]
[[Category:Enantiopure_drugs|Category:Enantiopure drugs]]
[[Category:Furans|Category:Furans]]
[[Category:葛蘭素史克|Category:葛蘭素史克]]
[[Category:Oximes|Category:Oximes]]
[[Category:Carbamates|Category:Carbamates]]